Paul F. Lubetkin

Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark.

OMRIX Biopharmaceuticals, Inc. specializes in the manufacture and development of biosurgical and passive immunotherapy products. Its product range encompasses hemostatic, surgical, and immunotherapy solutions. The firm offers solutions for bleeding control, surgical operations, and biodefense applications. The company was founded by Robert Taub in 1995 and is headquartered in Somerville, NJ.

Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.

Glycadia, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for the prevention and treatment of kidney, eye, cardiovascular, and related diseases resulting from diabetes. The private company is based in Philadelphia, PA, and has subsidiaries in the United States. The company's science is based on recent discoveries concerning the causal role of circulating glycated. Glycadia's experienced R&D team is bringing new scientific discoveries to clinical trials of innovative products for complications of diabetes, including nephropathy, retinopathy, and cardiovascular disease.

Part of Pfizer Inc., Pfizer Pharmaceuticals, Inc. is an American company that manufactures pharmaceutical products.